$33.03
2.48% today
Nasdaq, Apr 02, 09:19 pm CET
ISIN
US92243G1085
Symbol
PCVX
Sector
Industry

Vaxcyte Inc Stock price

$32.23
-39.87 55.30% 1M
-83.31 72.10% 6M
-49.63 60.63% YTD
-34.50 51.70% 1Y
+8.42 35.36% 3Y
+6.08 23.25% 5Y
+6.08 23.25% 10Y
Nasdaq, Closing price Tue, Apr 01 2025
-5.53 14.65%
ISIN
US92243G1085
Symbol
PCVX
Sector
Industry

Key metrics

Market capitalization $4.15b
Enterprise Value $2.47b
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
P/B ratio (TTM) P/B ratio 1.22
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-569.55m
Free Cash Flow (TTM) Free Cash Flow $-571.79m
Cash position $1.75b
EPS (TTM) EPS $-3.88
P/E forward negative
Short interest 11.07%
Show more

Is Vaxcyte Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,807 stocks worldwide.

Vaxcyte Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

10 Analysts have issued a Vaxcyte Inc forecast:

10x Buy
100%

Analyst Opinions

10 Analysts have issued a Vaxcyte Inc forecast:

Buy
100%

Financial data from Vaxcyte Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
- -
-
100%
- Direct Costs 16 16
56% 56%
-
-16 -16
56% 56%
-
- Selling and Administrative Expenses 61 61
52% 52%
-
- Research and Development Expense 477 477
43% 43%
-
-554 -554
45% 45%
-
- Depreciation and Amortization 16 16
56% 56%
-
EBIT (Operating Income) EBIT -570 -570
45% 45%
-
Net Profit -464 -464
15% 15%
-

In millions USD.

Don't miss a Thing! We will send you all news about Vaxcyte Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Vaxcyte Inc Stock News

Positive
Seeking Alpha
2 days ago
Vaxcyte, Inc.'s positive results achieved from phase 2 dose-finding study using VAX-24 for the prevention of invasive pneumococcal disease in infants; Further post 4 dose data expected 2nd of 2025. It is expected that the 7 major pneumococcal disease markets are to reach a value of $11.6 billion by 2035. VAX-24 goes beyond that of Prevnar 20 in terms of targeting 4 more serotypes than it.
Negative
Investors Business Daily
2 days ago
Biotech stocks were hammered Monday after Peter Marks, a top FDA official, resigned amid a clash with Robert F. Kennedy Jr. The post Moderna, Vaxcyte, Novavax Hammered After Key FDA Official Peter Marks Resigns appeared first on Investor's Business Daily.
Neutral
GlobeNewsWire
2 days ago
-- At All Doses Evaluated, VAX-24 Was Well-Tolerated and Demonstrated a Safety and Tolerability Profile Similar to Prevnar 20® (PCV20) -- -- At All Doses Evaluated, VAX-24 Elicited Substantial Immune Responses Following Primary  Three-Dose Immunization Series; Topline Results Also Include Interim Booster Dose IgG Data Showing Robust Memory Responses Across All Doses -- -- Dose-Dependent Immune ...
More Vaxcyte Inc News

Company Profile

Vaxcyte, Inc., a biopharmaceutical company, develops vaccines for infectious diseases. It offers conjugate, pneumococcal conjugate, and complex antigen-based vaccines. The company has a license to Sutro Biopharma's Xpress CF platforms for cell free protein synthesis and site-specific conjugation. Vaxcyte, Inc. was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May, 2020. The company was incorporated in 2013 and is headquartered in Foster City, California.

Head office United States
CEO Grant Pickering
Employees 414
Founded 2013
Website www.vaxcyte.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today